Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 | Contract Pharma

What are you searching for?

Sign in

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Cangene Corp.’s Varicella zoster immune globulin (VariZIG) has received orphan drug designation from the FDA for passive immunization for the treatment of exposed, susceptible individuals who are at risk of complications from varicella. This designation would give the drug seven years of market exclusivity if marketing approval is obtained and certain regulatory filing fees will be waived.

“This designation is another step in our commitment to address the unmet medical need faced by susceptible individuals who are exposed to chickenpox. It builds on the expanded access investigational new drug protocol that was approved in January by the FDA,” said Dr. John Langstaff, Cangene’s president and chief executive officer.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters